Skip to content

MoonLake Immunotherapeutics

US · MLTX #3305 by market cap Listed 2020
11.07 +0.04 +0.36%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 10.94 -0.82%
After-hours 11.07 0.00%
22.169.5511.072026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on MLTX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -22.5% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 6.4% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Return on equity -60.5% Better than 8%
Return on invested capital -53.4% Better than 5%
Momentum D+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -29.8% Better than 18%
6-month return -39.1% Better than 13%
12-month return (ex latest month) -2.6% Better than 30%
Distance below 52-week high 52.5% Better than 17%
Financial Health B

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 9.3x Better than 93%
Debt to assets 17.8% Better than 59%
Interest coverage -30.7x Better than 9%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 87.5% Better than 69%
Upside to average target 221.3% Better than 95%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -11.44%
1M +7.27%
3M -30.25%
6M -35.07%
YTD -16.01%
1Y -14.85%
3Y -74.06%
5Y +11.59%

Key statistics

Price & volume

Prev close
11.03
Open
10.79
Day range
10.73 - 11.31
Avg price
11.08
Volume
1.72M
Turnover
19.10M
Amplitude
5.26%
52-week range
9.46 - 23.29

Valuation

P/E
-3.14
P/E (TTM)
-3.02
P/B
2.47
EPS
-3.53
Net profit
-300.43M
Net assets
381.62M

Share structure

Market cap
942.13M
Float cap
601.79M
Shares out
85.11M
Float shares
54.36M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2020-10-20
52-week range 12% of range
9.46 23.29

52.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-25.01M net over the window

Short interest

Shares short
5.47M
As of
2026-10-30

Frequently asked questions

What is the current stock price of MoonLake Immunotherapeutics (MLTX)?

MoonLake Immunotherapeutics last traded at 11.07. This page shows a periodic quote snapshot. Check the displayed quote time.

What is MoonLake Immunotherapeutics's market cap?

About 942.13M.

What is the P/E ratio of MoonLake Immunotherapeutics?

The trailing twelve-month P/E is -3.02. The Valuation tab shows it against the stock's own five-year range.

Does MoonLake Immunotherapeutics pay a dividend?

MoonLake Immunotherapeutics does not currently pay a regular dividend.

Is MoonLake Immunotherapeutics a buy according to analysts?

The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 35.57, which implies 221.3% upside from the current price. This is not investment advice.

What is MoonLake Immunotherapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates MoonLake Immunotherapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

MoonLake Immunotherapeutics discussion 0 comments

Add a comment